



***In Vitro* Metabolic Stability of ALC-0159 in CD-1/ICR Mouse, Sprague Dawley Rat, Cynomolgus Monkey, and Human Liver S9 Fractions**

Sponsor	Acuitas Therapeutics Inc. 6190 Agronomy Road, Suite 402 Vancouver BC V6T 1Z3 Canada
Testing Facility	Medicilon Preclinical Research (Shanghai) LLC 585 Chuanda Rd, Pudong Shanghai 201299 China
Study Monitor	(b) (6) Acuitas Therapeutics Inc. (b) (6)
Study Director	(b) (6) Medicilon Preclinical Research (Shanghai) LLC (b) (6) (b) (6)
Alternate Contact	(b) (6) Medicilon Preclinical Research (Shanghai) LLC (b) (6)
Study Identification	01049-20021
Experimental Start Date	2020-06-19
Experimental Completion Date	2020-06-24
Number of Pages in Report	31

090177e194a20c6f\Approved\Approved On: 12-Aug-2020 17:56 (GMT)



TABLE OF CONTENTS

SUMMARY	3
SIGNATURES	4
1. OBJECTIVE	5
2. MATERIALS	5
2.1 Test Article.....	5
2.2 Positive Controls	5
2.3 Internal Standard.....	5
2.4 Liver S9 Fractions.....	5
2.5 Coenzymes and Pore-forming Agent.....	6
3. EXPERIMENTAL PROCEDURES	6
4. BIOANALYSIS	8
4.1 Instruments.....	8
4.2 LC/MS/MS Conditions	8
4.3 Detection of ALC-0159	8
5. DATA ANALYSIS	9
6. RESULTS	9
7. CONCLUSIONS	9
8. APPENDICES	14



Medicilon Preclinical Research (Shanghai) LLC
Test Article: ALC-0159
Study No.: 01049-20021

SUMMARY

This study evaluated the *in vitro* metabolic stability of ALC-0159 in liver S9 fractions of CD-1/ICR mouse, Sprague Dawley rat, cynomolgus monkey, and human. ALC-0159 was stable after an approximately 2-hour incubation with liver S9 from all these species.

090177e194a20c6f\Approved\Approved On: 12-Aug-2020 17:56 (GMT)



SIGNATURES

Compliance

This was a non-GLP study and was not conducted under full compliance with Good Laboratory Practice (GLP) regulations. Analyses were conducted according to an approved protocol and Standard Operating Procedures (SOPs) of Medicilon Preclinical Research (Shanghai) LLC. All data are documented in analysts' laboratory notebooks and electronic document management systems of Medicilon Preclinical Research (Shanghai) LLC. The content of this report has been reviewed against the raw data listings, summary tables and protocol for accuracy of the report.


Study Director Approval:

(b) (6)


Study Director

2020/08/10
Date

Sponsor Approval:

(b) (6)


Study Monitor

August 10, 2020
Date

090177e194a20c6fApproved\Approved On: 12-Aug-2020 17:56 (GMT)



1. OBJECTIVE

To evaluate the *in vitro* metabolic stability of ALC-0159 in liver S9 fractions from different species.


2. MATERIALS

2.1 Test Article

Name: ALC-0159

Molecular Formula: C₃₀H₆₀NO (C₂H₄O)_n (n = 45~50)

MW (g/mol): ~2400-2600



2.2 Positive Controls

Compound Name	Vendor	CAS No.	Cat. No.	Lot No.	Molecular Weight
Testosterone	Aladdin	58-22-0	T102169	K1505051	288.42
7-hydroxycoumarin	J&K Scientific	93-35-6	153384	L630I04	162.14

2.3 Internal Standard

Compound Name	Vendor	CAS No.	Cat. No.	Lot No.	Molecular Weight
Verapamil hydrochloride	TCI	152-11-4	V0118	RFMWJ-RL	491.06
Tolbutamide	Sigma-Aldrich	64-7-7	46968	BCBV8457	270.35

2.4 Liver S9 Fractions

The following pooled liver S9 fractions of CD-1/ICR mouse, Sprague Dawley rat, cynomolgus monkey, and human were stored in a -70°C ultra low temperature freezer prior to use.



Species	Manufacturer	Cat. No.	Lot No.	Protein Concentration (mg/mL)
CD-1/ICR mouse (male)	XenoTech	M1000.S9	1310210	20
Sprague Dawley rat (male)	XenoTech	R1000.S9	1310212	20
Cynomolgus monkey (male)	XenoTech	P2000.S9	0910273	20
Human (mixed gender)	BioreclamationIVT	X008023	BKY	20

2.5 Coenzymes and Pore-forming Agent

NADPH (reduced β -nicotinamide adenine dinucleotide 2'-phosphate) tetrasodium salt was stored at 2~8°C in a refrigerator prior to use. UDPGA (uridine-diphosphate-glucuronic acid trisodium salt) and alamethicin were stored in a -20°C freezer prior to use.

Compound Name	Manufacturer	Cat. No.	Molecular Weight	Purity
NADPH	Roche Diagnostic	10621706001	833.35	97%
UDPGA	Sigma	U6751	646.23	≥ 98
Alamethicin	Aladdin	A132913	1964.3078	99%

3. EXPERIMENTAL PROCEDURES

3.1 Stock solutions preparation:

1.90 mg of ALC-0159 was weighed and dissolved in 76 μ L of DMSO to obtain a 10 mM stock solution. 2.547 mg of testosterone was weighed and dissolved in 551.93 μ L of DMSO to obtain a 16 mM solution. A 10 mM testosterone stock solution was then prepared by adding 60 μ L DMSO to 100 μ L of the 16 mM testosterone solution. 3.97 mg of 7-hydroxycoumarin was weighed and dissolved in 1224.25 μ L of DMSO to obtain a 20 mM solution. A 10 mM 7-hydroxycoumarin stock solution was then prepared by adding 100 μ L DMSO to 100 μ L of the 20 mM 7-hydroxycoumarin solution. 5 mg of alamethicin was weighed and dissolved in 495 μ L of 100 mM potassium phosphate buffer to obtain a 10 mg/mL alamethicin solution.

3.2 0.5 mM spiking solutions preparation:

Spiking Solution of Test Article or Positive Control			
Conc. of Stock Solution (mM)	Volume of Stock Solution (μ L)	Volume of MeOH (μ L)	Final Concentration (mM)
10	10	190	0.5

090177e194a20c6f\Approved\Approved On: 12-Aug-2020 17:56 (GMT)



3.3 Preparation of 1.5× liver S9 suspensions (with alamethicin) containing test article or positive control:

1.5× Liver S9 Suspension (with Alamethicin) Containing Test Article or Positive Control						
Livers S9		0.5 mM Spiking Solution (μL)	10 mg/ml Alamethicin Solution	100 mM potassium phosphate buffer containing 5 mM of MgCl ₂ (pH 7.4) (μL)	Final Concentration	
Conc. of Stock Solution (mg/mL)	Volume of Stock Solution (μL)				Liver S9 Protein (mg/mL)	Compound (μM)
20	37.5	1.5	1.9	459.1	1.5	1.5

3.4 1.5× liver S9 suspensions (with alamethicin) containing test article or positive control were kept on ice for 15 minutes.

3.5 28.51 mg of NADPH was weighed and dissolved in 2.851 mL of 100 mM potassium phosphate buffer to obtain a 12 mM NADPH working solution. 25 mg of UDPGA was weighed and dissolved in 6.448 mL of 100 mM potassium phosphate buffer to obtain a 6 mM UDPGA working solution. 2.8 mL of 12 mM NADPH working solution was added into 2.8 mL of 6 mM UDPGA working solution to obtain a 6 mM NADPH and 3 mM UDPGA mixed working solution. This mixed working solution was then pre-warmed at 37°C.

3.6 30μL of liver S9 suspension (with alamethicin) containing 1.5 μM test article or positive control was added to 96-well plates in duplicate for each time point (0, 15, 30, 60, 90, and 120 min).

3.7 96-well incubation plates were pre-warmed at 37°C for 5 min.

3.8 For 0 min samples: 450 μL of ethanol containing internal standard (IS solution) was added before 15 μL of pre-warmed mixed working solution (6 mM NADPH and 3 mM UDPGA) was added.

3.9 For other samples (15, 30, 60, 90, and 120 min): 15 μL of pre-warmed mixed working solution (6 mM NADPH and 3 mM UDPGA) was added to initiate the reaction.

Volume (μL)			Final Concentration in Incubation Mixture		
1.5× Liver S9 Suspension Containing Test Article or Positive Control	3×NADPH Working Solution	Total	Liver S9 Protein (mg/mL)	Test Article or Positive Control (μM)	NADPH (mM)
30	15	45	0.5	1	2

The samples were incubated at 37°C and 450 μL of IS solution was added to stop the reaction at the corresponding time points (15, 30, 60, 90, and 120 min).

090177e194a20c6fApproved\Approved On: 12-Aug-2020 17:56 (GMT)



3.10 After quenching, the plates were shaken at 600 rpm for 10 min and then centrifuge at 6,000 rpm for 15 min.

3.11 Then 200 μ L of the supernatant from each well was transferred into a 96-well sample plate for LC-MS/MS analysis.

4. BIOANALYSIS

4.1 Instruments

SHIMADZU: UPLC system

Sciex Triple Quad 6500+ with ESI ion source

4.2 LC/MS/MS Conditions

Column: Agilent Zorbax SB-CN 3.5 μ m (100 mm*2.1 mm)

Gradient for ALC-0159:

Time (min)	Solvent A (%)	Solvent B (%)
0.00	80	20
0.40	30	70
1.60	10	90
2.70	10	90
2.71	80	20
3.00	80	20

Solvent A: 0.1% formic acid in water

Solvent B: 0.1% formic acid in acetonitrile

Flow rate: 600 μ L/min

Column temperature: 40°C

Autosampler temperature: 4°C

MS Conditions: MRM detection

Compound	Q1(m/z)	Q3(m/z)	DP	CE	Retention Time (min)
ALC-0159	1164.00	494.70	45	71	~1.33
Tolbutamide (IS)	271.10	172.00	70	18	~1.03

4.3 Detection of ALC-0159

Representative chromatograms of ALC-0159 in each matrix are shown in [Appendix 1](#).



5. DATA ANALYSIS

The % remaining parent compound (ALC-0159 or positive control, testosterone and 7-hydroxycoumarin) was calculated by dividing the peak area ratio (test article peak area/internal standard peak area) by the time zero peak area ratio. The natural logarithm of % remaining parent compound was plotted against time, and the slope of the regression line was determined. The elimination constant and half-life were calculated, when possible, as indicated below.

Elimination rate constant (k) = - slope

Half-life ($t_{1/2}$) = 0.693/k

6. RESULTS

A summary of the % remaining parent compound and half-life of ALC-0159 obtained from a 2-hour incubation with liver S9 from CD-1/ICR mouse, Sprague Dawley rat, cynomolgus monkey, and human is presented in [Table 1](#). The stability of ALC-0159 over time in each matrix is shown in [Figure 1](#). Raw data is presented in [Appendix 2](#).

The liver S9 used in this study were tested for activity using metabolism control substrates under incubation conditions identical to those used for ALC-0159. The enzymes were found to exhibit satisfactory activity as determined by significant consumption of the positive control compounds (testosterone and 7-hydroxycoumarin) during the 2-hour incubation period, hence the test systems were considered to have yielded valid results. A summary of the % remaining parent compound and half-life of testosterone and 7-hydroxycoumarin is provided in [Table 1](#). The stability of testosterone and 7-hydroxycoumarin over time in each matrix is shown in [Figure 2](#) and [Figure 3](#), respectively. Raw data for controls is presented in [Appendix 3](#) (testosterone) and [Appendix 4](#) (7-hydroxycoumarin).

7. CONCLUSIONS

This study evaluated the *in vitro* metabolic stability of ALC-0159 in liver S9 fractions of CD-1/ICR mouse, Sprague Dawley rat, cynomolgus monkey, and human. ALC-0159 was stable after an approximately 2-hour incubation with liver S9 from all these species.



Table 1. Summary of Liver S9 Stability of ALC-0159 , Testosterone and 7-Hydroxycoumarin


Compounds	Species		Percent Remaining (%)						T _{1/2} (minute)
			0 min	15 min	30 min	60 min	90 min	120 min	
ALC-0159	CD-1/ICR Mouse	Mean	100.00	98.93	91.10	102.85	90.75	106.76	>120
		RSD of Area Ratio	0.02	0.03	0.03	0.00	0.04	0.03	
	Sprague Dawley Rat	Mean	100.00	84.38	90.87	97.97	93.51	92.70	>120
		RSD of Area Ratio	0.12	0.02	0.08	0.06	0.03	0.03	
	Cynomolgus Monkey	Mean	100.00	91.30	97.96	105.56	108.33	105.74	>120
		RSD of Area Ratio	0.02	0.08	0.01	0.11	0.05	0.13	
Human	Mean	100.00	106.73	107.60	104.97	109.36	119.59	>120	
	RSD of Area Ratio	0.05	0.00	0.01	0.00	0.01	0.03		
Testosterone	CD-1/ICR Mouse	Mean	100.00	59.38	35.71	6.89	BQL	BQL	15.5
		RSD of Area Ratio	0.05	0.11	0.01	0.16	N/A	N/A	
	Sprague Dawley Rat	Mean	100.00	BQL	BQL	BQL	BQL	BQL	N/A
		RSD of Area Ratio	0.05	N/A	N/A	N/A	N/A	N/A	
	Cynomolgus Monkey	Mean	100.00	81.12	68.58	45.76	27.19	16.74	46.6
		RSD of Area Ratio	0.11	0.11	0.02	0.06	0.02	0.08	
Human	Mean	100.00	63.69	17.40	BQL	BQL	BQL	11.9	
	RSD of Area Ratio	0.00	0.02	0.09	N/A	N/A	N/A		
7-Hydroxycoumarin	CD-1/ICR Mouse	Mean	100.00	40.06	16.68	3.57	1.89*	1.54*	12.5
		RSD of Area Ratio	0.00	0.11	0.02	0.17	0.18	0.20	
	Sprague Dawley Rat	Mean	100.00	71.60	48.00	26.17*	13.71*	11.92*	28.3
		RSD of Area Ratio	0.08	0.04	0.07	0.06	0.00	0.04	
	Cynomolgus Monkey	Mean	100.00	80.70	64.55	38.33	23.76	16.34	44.8
		RSD of Area Ratio	0.04	0.04	0.05	0.00	0.01	0.04	
Human	Mean	100.00	69.01	43.17	19.16	8.29	3.68	25.0	
	RSD of Area Ratio	0.02	0.00	0.04	0.03	0.03	0.12		

* The compound showed biphasic metabolic kinetics, i.e., an initial fast disappearance phase was followed by a slow disappearance phase. The data points marked with * were in the slow disappearance phase and were excluded from half-life calculation. BQL = Below quantification limit; N/A = not applicable

090177e194a20c6fApproved\Approved On: 12-Aug-2020 17:56 (GMT)




Figure 1. Stability of ALC-0159 in Mouse, Rat, Monkey and Human Liver S9



090177e194a20c6f\Approved\Approved On: 12-Aug-2020 17:56 (GMT)




Figure 2. Stability of Testosterone in Mouse, Rat, Monkey and Human Liver S9



090177e194a20c6f\Approved\Approved On: 12-Aug-2020 17:56 (GMT)



Figure 3. Stability of 7-Hydroxycoumarin in Mouse, Rat, Monkey and Human Liver S9



090177e194a20c6f\Approved\Approved On: 12-Aug-2020 17:56 (GMT)



8. APPENDICES

Appendix 1 – Representative Chromatograms of ALC-0159 in Mouse, Rat, Monkey and Human Liver S9

Appendix 2 – Stability of ALC-0159 in Mouse, Rat, Monkey and Human Liver S9 – Raw Data

Appendix 3 – Stability of Testosterone in Mouse, Rat, Monkey and Human Liver S9 – Raw Data

Appendix 4 – Stability of 7-Hydroxycoumarin in Mouse, Rat, Monkey and Human Liver S9 – Raw Data

Appendix 5 – 01049-20021-S9 stability_protocol



Medicilon Preclinical Research (Shanghai) LLC
Test Article: ALC-0159
Study No.: 01049-20021


APPENDIX 1

Representative Chromatograms of ALC-0159 in Mouse, Rat, Monkey and Human Liver S9


090177e194a20c6f\Approved\Approved On: 12-Aug-2020 17:56 (GMT)




CD 1/ICR mouse




Sprague Dawley rat



Cynomolgus monkey



Human



090177e194a20c6fApproved/Approved On: 12-Aug-2020 17:56 (GMT)



Medicilon Preclinical Research (Shanghai) LLC
Test Article: ALC-0159
Study No.: 01049-20021

APPENDIX 2

Stability of ALC-0159 in Mouse, Rat, Monkey and Human Liver S9 – Raw Data

090177e194a20c6f\Approved\Approved On: 12-Aug-2020 17:56 (GMT)



Compounds	Species	Time(min)	Raw Data					
			Analyte Peak Area (counts)	Analyte Peak Area (counts)	IS Peak Area (counts)	IS Peak Area (counts)	Area Ratio	Area Ratio
ALC-0159	CD-1/ICR Mouse	0	5.08E+04	5.05E+04	3.57E+07	3.62E+07	0.001	0.001
		15	5.09E+04	4.82E+04	3.58E+07	3.55E+07	0.001	0.001
		30	4.48E+04	4.74E+04	3.58E+07	3.61E+07	0.001	0.001
		60	5.11E+04	5.11E+04	3.52E+07	3.56E+07	0.001	0.001
		90	4.47E+04	4.65E+04	3.59E+07	3.56E+07	0.001	0.001
		120	5.21E+04	5.42E+04	3.55E+07	3.55E+07	0.001	0.002
ALC-0159	Sprague Dawley Rat	0	5.46E+04	6.41E+04	2.42E+07	2.40E+07	0.002	0.003
		15	5.31E+04	5.16E+04	2.51E+07	2.51E+07	0.002	0.002
		30	5.82E+04	5.24E+04	2.46E+07	2.47E+07	0.002	0.002
		60	6.09E+04	5.58E+04	2.43E+07	2.40E+07	0.003	0.002
		90	5.90E+04	5.65E+04	2.49E+07	2.51E+07	0.002	0.002
		120	5.66E+04	5.43E+04	2.42E+07	2.44E+07	0.002	0.002
ALC-0159	Cynomolgus Monkey	0	6.60E+04	6.44E+04	2.41E+07	2.42E+07	0.003	0.003
		15	5.61E+04	6.26E+04	2.42E+07	2.40E+07	0.002	0.003
		30	6.35E+04	6.29E+04	2.39E+07	2.39E+07	0.003	0.003
		60	6.38E+04	7.33E+04	2.44E+07	2.38E+07	0.003	0.003
		90	7.46E+04	6.96E+04	2.47E+07	2.46E+07	0.003	0.003
		120	6.16E+04	7.28E+04	2.37E+07	2.34E+07	0.003	0.003
ALC-0159	Human	0	5.93E+04	5.62E+04	3.36E+07	3.40E+07	0.002	0.002
		15	6.18E+04	6.07E+04	3.37E+07	3.34E+07	0.002	0.002
		30	6.23E+04	6.19E+04	3.37E+07	3.38E+07	0.002	0.002
		60	6.08E+04	6.08E+04	3.40E+07	3.37E+07	0.002	0.002
		90	6.34E+04	6.28E+04	3.37E+07	3.38E+07	0.002	0.002
		120	7.07E+04	6.69E+04	3.38E+07	3.35E+07	0.002	0.002

090177e194a20c6f\Approved\Approved On: 12-Aug-2020 17:56 (GMT)



Medicilon Preclinical Research (Shanghai) LLC
Test Article: ALC-0159
Study No.: 01049-20021

APPENDIX 3

Stability of Testosterone in Mouse, Rat, Monkey and Human Liver S9 – Raw Data

090177e194a20c6f\Approved\Approved On: 12-Aug-2020 17:56 (GMT)



Compounds	Species	Time(min)	Raw Data					
			Analyte Peak Area (counts)	Analyte Peak Area (counts)	IS Peak Area (counts)	IS Peak Area (counts)	Area Ratio	Area Ratio
Testosterone	CD-1/ICR Mouse	0	1.74E+04	1.71E+04	5.35E+05	5.68E+05	0.032	0.030
		15	1.06E+04	1.16E+04	6.22E+05	5.77E+05	0.017	0.020
		30	6.44E+03	6.29E+03	5.72E+05	5.69E+05	0.011	0.011
		60	1.10E+03	1.37E+03	5.79E+05	5.69E+05	0.002	0.002
		90	LOD	LOD	5.84E+05	5.74E+05	LOD	LOD
		120	LOD	LOD	5.70E+05	5.75E+05	LOD	LOD
Testosterone	Sprague Dawley Rat	0	1.52E+04	1.62E+04	6.17E+05	6.14E+05	0.025	0.026
		15	LOD	LOD	6.05E+05	5.74E+05	LOD	LOD
		30	LOD	LOD	6.53E+05	5.96E+05	LOD	LOD
		60	LOD	LOD	5.75E+05	5.65E+05	LOD	LOD
		90	LOD	LOD	6.06E+05	5.80E+05	LOD	LOD
		120	LOD	LOD	5.98E+05	6.00E+05	LOD	LOD
Testosterone	Cynomolgus Monkey	0	1.68E+04	1.43E+04	5.88E+05	5.86E+05	0.029	0.024
		15	1.22E+04	1.32E+04	6.16E+05	5.72E+05	0.020	0.023
		30	1.08E+04	1.08E+04	6.04E+05	5.85E+05	0.018	0.018
		60	6.82E+03	7.12E+03	5.88E+05	5.64E+05	0.012	0.013
		90	4.29E+03	4.11E+03	5.87E+05	5.79E+05	0.007	0.007
		120	2.78E+03	2.38E+03	5.94E+05	5.69E+05	0.005	0.004
Testosterone	Human	0	1.66E+04	1.57E+04	5.95E+05	5.63E+05	0.028	0.028
		15	1.02E+04	1.05E+04	5.81E+05	5.81E+05	0.018	0.018
		30	3.05E+03	2.85E+03	5.88E+05	6.27E+05	0.005	0.005
		60	LOD	LOD	5.92E+05	5.75E+05	LOD	LOD
		90	LOD	LOD	6.07E+05	6.32E+05	LOD	LOD
		120	LOD	LOD	5.50E+05	5.76E+05	LOD	LOD

LOD = Limit of detection

090177e194a20c6f\Approved\Approved On: 12-Aug-2020 17:56 (GMT)



Medicilon Preclinical Research (Shanghai) LLC
Test Article: ALC-0159
Study No.: 01049-20021

APPENDIX 4

Stability of 7-Hydroxycoumarin in Mouse, Rat, Monkey and Human Liver S9 – Raw Data

090177e194a20c6f\Approved\Approved On: 12-Aug-2020 17:56 (GMT)



Compounds	Species	Time (min)	Raw Data					
			Analyte Peak Area (counts)	Analyte Peak Area (counts)	IS Peak Area (counts)	IS Peak Area (counts)	Area Ratio	Area Ratio
7-Hydroxycoumarin	CD-1/ICR Mouse	0	2.69E+04	2.63E+04	5.42E+05	5.29E+05	0.050	0.050
		15	1.20E+04	1.01E+04	5.59E+05	5.52E+05	0.021	0.018
		30	4.62E+03	4.53E+03	5.49E+05	5.54E+05	0.008	0.008
		60	1.11E+03	8.20E+02	5.54E+05	5.27E+05	0.002	0.002
		90	5.99E+02	4.34E+02	5.62E+05	5.30E+05	0.001	0.001
		120	3.69E+02	4.87E+02	5.59E+05	5.58E+05	0.001	0.001
7-Hydroxycoumarin	Sprague Dawley Rat	0	2.60E+04	2.51E+04	5.20E+05	5.61E+05	0.050	0.045
		15	1.88E+04	1.82E+04	5.37E+05	5.52E+05	0.035	0.033
		30	1.29E+04	1.20E+04	5.39E+05	5.52E+05	0.024	0.022
		60	6.94E+03	6.43E+03	5.38E+05	5.40E+05	0.013	0.012
		90	3.57E+03	3.60E+03	5.49E+05	5.56E+05	0.007	0.006
		120	2.92E+03	3.11E+03	5.32E+05	5.34E+05	0.005	0.006
7-Hydroxycoumarin	Cynomolgus Monkey	0	2.46E+04	2.60E+04	5.32E+05	5.32E+05	0.046	0.049
		15	2.18E+04	2.06E+04	5.53E+05	5.50E+05	0.039	0.037
		30	1.65E+04	1.74E+04	5.57E+05	5.45E+05	0.030	0.032
		60	9.83E+03	9.77E+03	5.40E+05	5.35E+05	0.018	0.018
		90	6.29E+03	6.06E+03	5.52E+05	5.40E+05	0.011	0.011
		120	4.19E+03	4.03E+03	5.23E+05	5.34E+05	0.008	0.008
7-Hydroxycoumarin	Human	0	2.65E+04	2.65E+04	5.32E+05	5.16E+05	0.050	0.051
		15	1.88E+04	1.83E+04	5.37E+05	5.24E+05	0.035	0.035
		30	1.23E+04	1.15E+04	5.49E+05	5.42E+05	0.022	0.021
		60	5.42E+03	5.06E+03	5.48E+05	5.33E+05	0.010	0.009
		90	2.28E+03	2.37E+03	5.55E+05	5.52E+05	0.004	0.004
		120	9.57E+02	1.11E+03	5.60E+05	5.53E+05	0.002	0.002

090177e194a20c6f\Approved\Approved On: 12-Aug-2020 17:56 (GMT)



Medicilon Preclinical Research (Shanghai) LLC
Test Article: ALC-0159
Study No.: 01049-20021

APPENDIX 5

01049-20021-S9 stability_protocol

090177e194a20c6f\Approved\Approved On: 12-Aug-2020 17:56 (GMT)



***In Vitro* Metabolic Stability of ALC-0159 in CD-1/ICR Mouse,
Sprague Dawley Rat, Cynomolgus Monkey, and Human Liver S9
Fractions**

Testing Facility

Medicilon Preclinical Research (Shanghai) LLC
585 Chuanda Road, Pudong
Shanghai 201299, China

Study Number

01049-20021

Study Director

(b) (6)

Sponsor

Acuitas Therapeutics Inc.

CONTENTS

1. INTRODUCTION.....3
1.1. Study Number.....3
1.2. Study Title3
1.3. Sponsor Representative3
1.4. Objective.....3
1.5. Compliance.....3
1.6. Testing Facility3
1.7. Personnel3
1.8. Study Schedule4
2. MATERIALS4
2.1. Test Article4
2.2. Positive Control and Internal Standard.....4
2.3. Liver Microsomes and Cofactor4
3. EXPERIMENTAL PROCEDURES5
4. BIOANALYSIS6
4.1. Instruments6
4.2. LC/MS/MS Conditions.....6
5. DATA ANALYSIS7
6. FINAL REPORT7
7. SIGNATURES8

090177e194a20c6f\Approved\Approved On: 12-Aug-2020 17:56 (GMT)

1. INTRODUCTION

1.1. Study Number

01049-20021

1.2. Study Title

In Vitro Metabolic Stability of ALC-0159 in CD-1/ICR Mouse, Sprague Dawley Rat, Cynomolgus Monkey, and Human Liver S9 Fractions

1.3. Sponsor Representative

(b) (6)

Acuitas Therapeutics Inc.
6190 Agronomy Road, Suite 402
Vancouver BC V6T 1Z3
Canada

(b) (6)

1.4. Objective

To evaluate the *in vitro* metabolic stability of ALC-0159 in liver S9 from different species.

1.5. Compliance

This is a non-GLP study and will be conducted according to the Standard Operating Procedures (SOPs) of Medicilon Preclinical Research (Shanghai) LLC.

1.6. Testing Facility

Medicilon Preclinical Research (Shanghai) LLC
585 Chuanda Road, Pudong, Shanghai 210299, China

1.7. Personnel

1.7.1. Study Director

(b) (6)

[Redacted]

1.7.2. Alternate Contact

(b) (6)

1.8. Study Schedule

Study Initiation Date:	Signature date by Study Director
Experiment Start Date:	To be included in the final report
Experiment Termination Date:	To be included in the final report
Draft Report Issue Date:	To be included in the final report


2. MATERIALS

2.1. Test Article

Name: ALC-0159

Molecular Formula: $C_{30}H_{60}NO (C_2H_4O)_n$ ($n = 45\sim 50$)

MW (g/mol): ~2400-2600



2.2. Positive Control and Internal Standard

Testosterone and 7-hydroxycoumarin will be used as positive controls. Tolbutamide will be used as internal standard. The sources will be documented in experimental records and presented in the report.

2.3. Liver Microsomes and Cofactor

Liver S9 fractions of CD-1/ICR mouse, Sprague Dawley rat, cynomolgus monkey and human were purchased from qualified supplier and stored in a -70°C ultra low temperature freezer.

NADPH (reduced β -Nicotinamide adenine dinucleotide 2'-phosphate tetrasodium salt) were purchased from qualified supplier and stored at $2\text{-}8^{\circ}\text{C}$ in a refrigerator.

UDPGA (uridine-diphosphate-glucuronic acid trisodium salt) and alamethicin were purchased from qualified suppliers and stored in a -20°C freezer.

The source and lot numbers will be documented in the experimental records and presented in the final report.

3. EXPERIMENTAL PROCEDURES

- (1) Preparation of stock solutions: Appropriate amount of test article or positive control is weighed and dissolved in DMSO to obtain a 10 mM stock solution.
- (2) Preparation of 0.5 mM spiking solutions:

Spiking Solution of Test Article or Positive Control			
Conc. of stock solution	Volume of stock solution (μL)	Volume of MeOH (μL)	Final Concentration
10 mM	10	190	0.5 mM

- (3) Preparation of 1.5× liver S9 suspensions with alamethicin containing test article or positive control:

1.5× Liver S9 Suspension with Alamethicin containing Test article or Positive control						
Livers S9		0.5 mM spiking solution (μL)	10 mg/ml Alamethicin	100 mM potassium phosphate buffer containing 5 mM of MgCl ₂ (pH 7.4) (μL)	Final Concentration	
Conc. of stock solution (mg/mL)	Volume of stock solution (μL)				Liver S9 protein (mg/mL)	Compound (μM)
20	37.5	1.5	1.9	459.1	1.5	1.5

- (4) 1.5× liver S9 suspensions with alamethicin containing test article or positive control are kept on ice for 15 minutes.
- (5) 3× master mix of cofactors (6 mM NADPH and 3 mM UDPGA in 100 mM potassium phosphate buffer containing 5 mM of MgCl₂, pH7.4) is prepared and then pre-warmed to 37°C.
- (6) 30 μL of liver S9 suspension with alamethicin containing 1.5 μM test article or positive control is added to 96-well plates in duplicate for each time point (0, 15, 30, 60, 90, and 120 min).
- (7) 96-well incubation plates (from Step 6) are pre-warmed at 37°C for 5 min.
- (8) For 0-min samples: 450 μL ethanol containing internal standard (IS solution) is added, followed by 15 μL pre-warmed 3× master mix of cofactors.

- (9) For the 15, 30, 60, 90, and 120 min samples, 15 μL pre-warmed 3 \times master mix of cofactors is added to initiate reaction.

Volume of final incubation system (μL)			Final Concentration			
1.5 \times Liver S9 Suspension with Alamethicin containing Test article or Positive control	3 \times Master Mix of Cofactors	Total Volume	Liver S9 protein (mg/mL)	Compound (μM)	UDPGA (mM)	NADPH (mM)
30	15	45	1	1	1	2

The samples are incubated at 37 °C and 450 μL IS solution (10ng/mL verapamil in ethanol) is added to stop the reaction at the corresponding time points (15, 30, 60, 90, and 120 min).

- (10) After quenching, shake the plates at 600 rpm for 10 min and then centrifuge them at 6,000 rpm for 15 min.
- (11) The plates are sealed and stored at -20 °C in a freezer until bioanalysis.
- (12) Thaw the plates at room temperature, centrifuge them at 6,000 rpm for 15 min, then transfer 200 μL of the supernatant from each well into a 96-well sample plate for LC-MS/MS analysis.

4. BIOANALYSIS

4.1. Instruments

SHIMADZU: UPLC system

Sciex Triple Quad 6500+ with ESI ion source

4.2. LC/MS/MS Conditions

Column: Agilent Zorbax SB-CN 3.5 μm (100mm*2.1mm)

Gradient Chromatography Parameters for ALC-0159:

Time (min)	Solvent A (%)	Solvent B (%)
0.00	80	20
0.40	30	70
1.60	10	90
2.70	10	90
2.71	80	20
3.00	80	20

Solvent A: 10mM ammonium formate, 0.1% Formic acid in water

Solvent B: 10mM ammonium formate, 0.1% Formic acid in acetonitrile

Flow rate: 500 μ L/min

Column temperature: 40 $^{\circ}$ C

Autosampler temperature: 4 $^{\circ}$ C

MS Conditions: MRM detection

Compound	Q1(m/z)	Q3(m/z)	DP	CE	Retention
ALC-0159	1164.00	494.70	45	71	~1.30
Tolbutamide (IS)	271.10	172.00	70	18	~1.02

5. DATA ANALYSIS

The % remaining will be calculated by dividing the peak area ratio (test article peak area/ internal standard peak area) by the time zero peak area ratio. The natural logarithm of % remaining will be plotted against time, and the slope of the regression line will be determined. Then elimination constant and half-life will be calculated as below.

$$\text{Elimination rate constant (k)} = - \text{slope}$$

$$\text{Half-life (t}_{1/2}\text{)} = 0.693/k$$

6. FINAL REPORT

After completion of the study, a draft report including the results, analysis and discussion will be sent to the Sponsor in Microsoft Word format.

One month after issuance of the draft report, if no requested revisions or instructions to finalize have been communicated by the Sponsor, the draft report will be issued as a final report, signed by the Study Director, and submitted to the Sponsor in Adobe Acrobat PDF format, containing hyperlinks, as applicable. Any modifications or changes to the draft report requested one month after issuance of the draft will be performed at additional cost to the Sponsor.

7. SIGNATURES

(b) (6)

Sponsor Representative

June 17, 2020

Date

Study Director Approval

(b) (6)

Study Director

2020/06/17
Date